Trovagene Q1 Revenues Fall 6 Percent as Net Loss Swells | GenomeWeb

NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Tuesday that its first quarter revenues fell nearly 6 percent year over year as its net loss increased 43 percent.

For the three months ended March 31, the liquid biopsy MDx developer reported revenues of $120,000 compared to $127,000 in Q1 2015, falling short of analysts' estimate of $260,000.

Trovagene reported $113,000 in royalty revenues compared to $125,000 in Q1 2015, and $7,000 in diagnostic service revenues, up from $2,000 in the year-ago quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.